A UK-based resource to support the monitoring and safe use of anti-TB drugs and second-line treatment of multidrug-resistant TB.
expert_opinion · Level V
Where this comes from
- Record sourced from PubMed, PMID 24928813.
- Also identified by DOI 10.1136/thoraxjnl-2014-205278 and PMC identifier 4345768.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Using the best available evidence and expert consensus, this document provides guidance for adverse effect monitoring in multidrug-resistant TB (MDR-TB). It includes recommendations for baseline tests, routine drug and toxicity monitoring guides as well as individual drug monographs for all drugs currently available in the UK to treat TB. These recommendations provide a structure through which healthcare professionals can better manage the complex drug regimens required for the treatment of MDR-TB; minimising the risk of adverse incidents and helping to improve patients' tolerance, compliance and treatment completion.
Medical subject headings
- Antitubercular Agents
- Practice Guidelines as Topic
- Tuberculosis, Multidrug-Resistant
- Tuberculosis, Pulmonary